Four major medical organizations unite to back evidence-based immunization standards for influenza, RSV, and COVID-19.
RT’s Three Key Takeaways:
- Unified Society Endorsement: Four leading medical societies have issued a consensus endorsement of influenza, respiratory syncytial virus (RSV), and COVID-19 vaccine recommendations for adult and pediatric populations.
- Clinical Clarity: The joint effort provides clinicians treating lung disease with clear guidance amid ongoing transitions and procedural stays in federal immunization advisory processes.
- Bedside Protection: Critical care and pulmonary leaders emphasized that preventative vaccination remains a vital clinical tool to reduce severe respiratory illness and hospitalizations.
A coalition of respiratory and critical care organizations has endorsed unified vaccine guidance for influenza, respiratory syncytial virus (RSV), and COVID-19 to protect patients with lung disease, according to the American Thoracic Society (ATS).
The Vaccine Guidance Review Panel includes experts from ATS, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Chest Physicians (CHEST), and the Society of Critical Care Medicine (SCCM). The panel unanimously endorsed the immunization development process and recommendations established by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the Infectious Diseases Society of America (IDSA).
The multi-society guidance aligns with Advisory Committee on Immunization Practices (ACIP) recommendations issued prior to June 2025. According to the organizations, the joint panel formed to provide a single, up-to-date reference for clinicians following federal changes within the Department of Health and Human Services (HHS) and ACIP that placed a temporary stay on multiple vaccine decisions dating back to May 2025.
“Clinicians and their patients with serious lung disease should not have to navigate a labyrinth of confusion, particularly as we face the upcoming respiratory virus season,” said Michelle Ng Gong, MD, president of ATS, in a news release. “The evidence-based vaccine recommendations endorsed by ATS, AAAAI, CHEST, and SCCM provide clinicians with confidence and practical vaccine guidance when treating patients at the highest risk of severe illness.”
Strengthening Preventative Respiratory Care
The endorsing societies highlighted the critical role preventative medicine plays in reducing severe disease burdens across acute, chronic, and intensive care settings.
“The work we are doing at the bedside is infinitely more effective when supported by a foundation of preventative medicine,” said Neil Freedman, MD, president of CHEST, in a news release. “By ensuring clarity of unified recommendations from the voice of the community that cares for those with chronic and acute respiratory diseases with the broader physician community, this multi-society partnership aims to provide education and protect equitable access to preventative medicine and care.”
Leaders in critical care medicine also noted the severe risks respiratory viral infections pose to vulnerable patient populations.
“As critical care professionals, we see firsthand the devastating consequences that respiratory viral illnesses can have on patients and families,” said Cherylee W. J. Chang, MD, president of SCCM, in a news release. “Vaccination remains one of our most effective tools to prevent severe disease. We strongly support the influenza, RSV, and COVID-19 vaccination recommendations from the AAP, ACOG, AAFP, and IDSA.”
“AAAAI strongly supports the adoption of evidence-based vaccine recommendations that help healthcare professionals make informed decisions and provide the best possible care for their patients,” said Carla Davis, MD, president of AAAAI. “These recommendations reflect the importance of scientific evidence, clinical expertise, and a shared commitment to protecting public health.”
